Enlivex Therapeutics (ENLV)
(Real Time Quote from BATS)
$1.47 USD
+0.02 (1.38%)
Updated Apr 26, 2024 03:28 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Enlivex Therapeutics Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 27 | 50 | 84 | 37 | 14 |
Receivables | NA | 0 | 0 | 0 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 2 | 2 | 1 | 1 |
Total Current Assets | 34 | 52 | 86 | 38 | 16 |
Net Property & Equipment | 2 | 10 | 3 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 5 | 6 | 1 | 0 |
Total Assets | 37 | 68 | 95 | 40 | 18 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 1 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 5 | 4 | 3 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 1 | 4 |
Total Current Liabilities | 6 | 7 | 5 | 4 | 6 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 4 | 5 | 1 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 7 | 11 | 10 | 5 | 6 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 2 | 2 | 1 |
Capital Surplus | 139 | 137 | 134 | 70 | 37 |
Retained Earnings | -112 | -83 | -52 | -38 | -26 |
Other Equity | 1 | 1 | 1 | 1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 30 | 57 | 85 | 35 | 11 |
Total Liabilities & Shareholder's Equity | 37 | 68 | 95 | 40 | 18 |
Total Common Equity | 100,029 | 57 | 85 | 35 | 11 |
Shares Outstanding | 18.50 | 18.40 | 18.30 | 13.40 | 10.30 |
Book Value Per Share | 5,406.98 | 3.09 | 4.65 | 2.65 | 1.10 |
Fiscal Year End for Enlivex Therapeutics Ltd falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 27 | 31 | 29 | 36 |
Receivables | NA | NA | 0 | 0 | 0 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 1 | 2 | 2 |
Total Current Assets | NA | 34 | 32 | 31 | 38 |
Net Property & Equipment | NA | 2 | 9 | 10 | 10 |
Investments & Advances | NA | NA | 0 | 7 | 7 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | NA | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 6 | 6 | 5 |
Total Assets | NA | 37 | 47 | 53 | 60 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 2 | 1 |
Current Portion Long-Term Debt | NA | NA | 0 | 0 | 0 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 4 | 3 | 4 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 0 | 0 | 0 |
Total Current Liabilities | NA | 6 | 4 | 5 | 5 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 4 | 4 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | 7 | 8 | 9 | 9 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | 2 | 2 | 2 | 2 |
Capital Surplus | NA | 139 | 139 | 138 | 138 |
Retained Earnings | NA | -112 | -103 | -97 | -90 |
Other Equity | NA | 1 | 1 | 1 | 1 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 30 | 39 | 44 | 51 |
Total Liabilities & Shareholder's Equity | NA | 37 | 47 | 53 | 60 |
Total Common Equity | 0 | 100,029 | 39 | 44 | 51 |
Shares Outstanding | 18.50 | 18.50 | 18.50 | 18.50 | 18.50 |
Book Value Per Share | 0.00 | 5,406.98 | 2.10 | 2.40 | 2.73 |